The
purified hyaluronan in LubriSyn CA is extracted from a microbial
source. Other oral hyaluronan (HA) products are made from things such
as rooster combs or chicken cartilage. The microbial biofermentation
results in a high molecular weight HA, and keeps it free from proteins,
dermatan, chondroitin sulfate and other glycosaminoglycan contamination
that may be found in other HA products.
LubriSyn CA is currently available online at lubrisyn.com and through our toll-free customer service line 800-901-8498.
LubriSyn CA is administered orally to your pet. Many pet owners put LubriSyn CA directly on their pet's food.
High
molecular weight HA like the HA in LubriSyn CA has been demonstrated in
the joints of dogs and rats as early as 30 minutes after oral
administration. The level peaks in most tissues in 4-6 hours. (Schauss,
Balogh, Polyak, Kiraly, & Janok, 2004)
LubriSyn
CA is an daily oral hyaluronan joint supplement. Adequan Canine is an
injectable drug given by veterinarians to dogs to help improve joint
function. Adequan is a polysulfated glycosaminoglycan that can increase
production of joint hyaluronan. It is recommended by Novartis Animal
Health to be given twice a week for four weeks; each injection has a
duration of effect lasting about three days. (Novartis 2005) Pets can
still be given Lubrisyn CA while receiving Adequan.
No.
LubriSyn CA is beneficial to the joint fluid. Cosequin is composed
primarily of glucosamine and chondroitin sulfate and works on
cartilage. (NutraMax Laboratories, Inc. 2005) LubriSyn CA and Cosequin
can work synergistically to improve joint health.
The
recommended daily oral dose for dogs is 1 teaspoon (5 ml) for dogs up
to 30 pounds body weight. For dogs between 30 and 60 pounds, we suggest
1 ½ teaspoons daily. For dogs between 60 and 100 pounds, 2 teaspoons.
The amount may be doubled for hard-working dogs.
LubriSyn CA provides viscosupplementation and is intended to help dogs and cats have as healthy joints as possible.
LubriSyn
CA is basically odorless and tasteless. Since LubriSyn CA contains
sodium hyaluronate, it might have a very slight salty taste to some
very sensitive palates.
Our safety studies have shown that even at five times the recommended dose for 60 days, there were no adverse effects.
There is no exact time. Most animals respond by seven to 14 days. Results vary depending upon the condition of the joints.
LubriSyn
CA is available only through veterinarians. LubriSyn CA (Allday
Products) does not set the retail price. LubriSyn CA comes in an 8.5
ounce (251 ml) bottle that should last a 30-60 pound dog about thirty
days.
Your
pet may need a slightly higher daily amount depending upon the
condition of their joints. First, try a double dose for one week to see
if there is a noticeable improvement. If there is no change,
discontinue use and observe for one more week. If you do not see a
worsening of signs after a week without LubriSyn CA, you may call the
toll-free number to request a full refund. LubriSyn CA has a
no-questions-asked guarantee. 1-800-901-8498 is our toll-free number.
We
know of no problems with acceptance of LubriSyn CA. It is odorless and
basically tasteless; some very sensitive palates may detect a slight
salty taste.
We
suggest using the freshest product possible, but if handled properly it
will last 12 months. LubriSyn CA is a sensitive product and can
deteriorate. We have added a minimal amount of preservatives to avoid
any deterioration. We have also taken steps during production and
shipping to ensure its integrity. The production date is printed on the
label.
Yes.
As with most liquid nutritional supplements, extreme hot or cold
temperatures can cause some breakdown. We recommend storing LubriSyn CA
between 40 and 90 degrees Fahrenheit (4 to 32 degrees centigrade). DO
NOT freeze LubriSyn CA.
No.
Hyaluronan is a naturally occurring substance found in the joints, skin
and other tissues of all mammals. LubriSyn CA is made from a microbial
source of hyaluronan along with a very small amount of sodium benzoate
and potassium sorbate as protectants.
LubriSyn CA can be given orally with a meal or between meals. The food should have no effect.
These are three different names for the same compound.
Bucci, LR, and AA Turpin. "Will the real hyaluronan please stand up?" J of Appl Nutr 54, no. 1 (2004): 10-33.
Cantor,
JO, and PP Nadkarni. "Hyaluronan: the Jekyll and Hyde molecule."
Inflamm Allergy Drug Targets 5, no. 4 (Dec 2006): 257-260.
Gotoh,
S, et al. "Effects of the molecular weight of hyaluronic acid and its
action mechanisms on experimental joint pain in rats." Ann Rheum Dis
52, no. 11 (Nov 1993): 817-822.
Ishimaru, JI,
N Ogi, S Mizuno, and AN Goss. "Quantitation of chondroitin-sulfates,
disaccharides and hyaluronan in normal, early and advanced
osteoarthritic sheep temporomandibular joints." Osteoarthritis
Cartilage 9, no. 4 (May 2001): 365-370.
Moreland,
LW. "Intra-articular hyaluronan (hyaluronic acid) and hylans for the
treatment of osteoarthritis: mechanisms of action." Arthritis Res Ther
5, no. 2 (2003): 54-67.
Nakamura, K, et al.
"High, but not low, molecular weight hyaluronan prevents
T-cell-mediated liver injury by reducing proinflammatory cytokines in
mice." J Gastroenterol 39, no. 4 (2004): 346-354.
Novartis. Clinical Studies. 2005. http://www.adequancanine.us/vet/en/vet_clinicalStudies.shtml (accessed Feb 22, 2007).
NutraMax Laboratories, Inc. 2005. http://www.nutramaxlabs.com/Brochures/Cosequin Dog Brochure.pdf (accessed Feb 22, 2007).
Ohkawara,
Y, G Tamura, T Iwasaki, A Tanaka, T Kikuchi, and K Shirato. "Activation
and transforming growth factor-beta production in eosinophils by
hyaluronan." Am J Respir Cell Mol Biol 23, no. 4 (Oct 2000): 444-451.
Schauss,
AG, LG Balogh, AG Polyak, RG Kiraly, and i GG Janok. "Absorption,
distribution and excretion of 99mtechnetium labeled hyaluronan after
single oral doses in rats and beagle dogs." FASEB j 18, no. 4 (2004):
A150-151.
Takahashi, T, et al. "A decreae in
the molecular weight of hyaluronic acid in synovial fluid from patients
with temporomandibular disorders." J Oral Pathol Med 33, no. 4 (Apr
2004): 224-229.
Yeung, RW, RL Chow, Samman N,
and K Chiu. "Short-term therapeutic outcome of intra-articular high
molecular weight hyaluronic acid injection for non-reducing disc
displacement of the temporomandibular joint." Oral Surg Oral Med Oral
Pathol Oral Radiol Endod 102, no. 4 (Oct 2006): 453-461.
